CA3125646A1 - Expansion de cellules modifiees et ses utilisations - Google Patents

Expansion de cellules modifiees et ses utilisations Download PDF

Info

Publication number
CA3125646A1
CA3125646A1 CA3125646A CA3125646A CA3125646A1 CA 3125646 A1 CA3125646 A1 CA 3125646A1 CA 3125646 A CA3125646 A CA 3125646A CA 3125646 A CA3125646 A CA 3125646A CA 3125646 A1 CA3125646 A1 CA 3125646A1
Authority
CA
Canada
Prior art keywords
cells
car
antigen
cell
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3125646A
Other languages
English (en)
Inventor
Lei Xiao
Chengfei PU
Zhiyuan CAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovative Cellular Therapeutics Holdings Ltd Grand Cayman
Original Assignee
Innovative Cellular Therapeutics Holdings Ltd Grand Cayman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/387,166 external-priority patent/US10869888B2/en
Application filed by Innovative Cellular Therapeutics Holdings Ltd Grand Cayman filed Critical Innovative Cellular Therapeutics Holdings Ltd Grand Cayman
Priority claimed from PCT/US2020/013099 external-priority patent/WO2020146743A1/fr
Publication of CA3125646A1 publication Critical patent/CA3125646A1/fr
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des méthodes permettant d'améliorer une réponse de lymphocytes T et/ou une expansion des cellules CAR et/ou un maintien in vivo et/ou in vitro. Par exemple, une méthode d'amélioration d'une thérapie à base de lymphocytes T consiste à administrer une population mixte de lymphocytes T comprenant des lymphocytes T modifiés comprenant un premier récepteur d'antigène chimère (CAR) et des lymphocytes T modifiés comprenant un second CAR, un domaine de liaison du premier CAR se liant à un premier antigène, et un domaine de liaison du second CAR se liant à un second antigène. Le premier antigène est différent du second antigène. Selon certains modes de réalisation, le premier CAR se lie à une molécule de surface ou à un antigène d'un leucocyte.
CA3125646A 2019-01-10 2020-01-10 Expansion de cellules modifiees et ses utilisations Pending CA3125646A1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962790783P 2019-01-10 2019-01-10
US62/790,783 2019-01-10
US201962799462P 2019-01-31 2019-01-31
US62/799,462 2019-01-31
US201962816497P 2019-03-11 2019-03-11
US62/816,497 2019-03-11
US201962817322P 2019-03-12 2019-03-12
US62/817,322 2019-03-12
US16/387,166 US10869888B2 (en) 2018-04-17 2019-04-17 Modified cell expansion and uses thereof
US16/387,166 2019-04-17
US201962846563P 2019-05-10 2019-05-10
US62/846,563 2019-05-10
US62/848,961 2019-05-16
US16/445,965 2019-06-19
US62/889,926 2019-08-21
US62/891,131 2019-08-23
US62/902,766 2019-09-19
US62/932,587 2019-11-08
PCT/US2020/013099 WO2020146743A1 (fr) 2019-01-10 2020-01-10 Expansion de cellules modifiées et ses utilisations

Publications (1)

Publication Number Publication Date
CA3125646A1 true CA3125646A1 (fr) 2020-07-16

Family

ID=77062633

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3125646A Pending CA3125646A1 (fr) 2019-01-10 2020-01-10 Expansion de cellules modifiees et ses utilisations

Country Status (1)

Country Link
CA (1) CA3125646A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563482A (zh) * 2021-08-03 2021-10-29 北京安北生物医药科技有限公司 Cd19靶向性的嵌合抗原受体及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563482A (zh) * 2021-08-03 2021-10-29 北京安北生物医药科技有限公司 Cd19靶向性的嵌合抗原受体及其应用
CN113563482B (zh) * 2021-08-03 2023-02-28 安北生物医药(宜兴)有限公司 Cd19靶向性的嵌合抗原受体及其应用

Similar Documents

Publication Publication Date Title
US10869888B2 (en) Modified cell expansion and uses thereof
US20220096546A1 (en) Modified Cell Expansion and Uses Thereof
EP3586852B1 (fr) Expansion de cellules modifiées et leurs utilisations
KR101976882B1 (ko) 세포 면역요법용 방법 및 조성물
KR20200120939A (ko) 변형된 만능성 줄기 세포, 및 제조 및 사용 방법
US20210137983A1 (en) Nk cell expansion and uses thereof
US20210060069A1 (en) Coupled redirected cells and uses thereof
US20210252059A1 (en) Engineered safety in cell therapy
US20210100841A1 (en) Presenting cell and use thereof in cell therapy
US20230201258A1 (en) Polyspecific Binding Molecules and their use in Cell Therapy
JP2020535796A (ja) strepタグ特異的キメラ受容体およびその使用
CN110819596B (zh) 具有增强的迁移能力的修饰的细胞
US11701385B2 (en) Modulation of cell function for immunotherapy
CN111826353B (zh) 调节t细胞功能和反应的方法
US20210024890A1 (en) Modulating t cell function and response
CN112779223B (zh) 偶联嵌合抗原受体细胞及其用途
US11981920B2 (en) Modified cell with enhanced migration capability
US11739136B2 (en) Inducible dominant negative PD-1 and uses in adoptive cell therapy
US20230226113A1 (en) Vaccine and Uses thereof in Cell Therapy
EP3892720A1 (fr) Cellule présentatrice et son utilisation en thérapie cellulaire
CA3125646A1 (fr) Expansion de cellules modifiees et ses utilisations
US20240075061A1 (en) Cell therapy activating lymphocyte in tme
US20210371492A1 (en) Anti-GCC Antibody and CAR thereof for Treating Digestive System Cancer
US20230293691A1 (en) Cell/gene therapies targeting mage-a4 peptide
JP2022531814A (ja) 改変細胞の増幅およびその応用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220902

EEER Examination request

Effective date: 20220902

EEER Examination request

Effective date: 20220902

EEER Examination request

Effective date: 20220902

EEER Examination request

Effective date: 20220902